Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Up 1,022.5% in January

Vincerx Pharma, Inc. (NASDAQ:VINC - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 4,710,000 shares, an increase of 1,022.5% from the December 31st total of 419,600 shares. Based on an average trading volume of 6,840,000 shares, the days-to-cover ratio is presently 0.7 days.

Vincerx Pharma Trading Down 17.0 %

Shares of VINC stock traded down $0.34 during trading on Tuesday, hitting $1.65. The company's stock had a trading volume of 415,491 shares, compared to its average volume of 243,087. The company has a market cap of $55.52 million, a PE ratio of -1.60 and a beta of 1.48. The business has a fifty day moving average of $4.09 and a 200-day moving average of $8.90. Vincerx Pharma has a 52 week low of $1.62 and a 52 week high of $187.44.

Institutional Investors Weigh In On Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP boosted its stake in Vincerx Pharma, Inc. (NASDAQ:VINC - Free Report) by 359.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 328,533 shares of the company's stock after acquiring an additional 256,967 shares during the period. Marshall Wace LLP owned 1.11% of Vincerx Pharma worth $266,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 44.02% of the company's stock.

Analyst Ratings Changes

Separately, Leerink Partners dropped their price target on shares of Vincerx Pharma from $80.00 to $40.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.